Paper23933716
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
Haddish-Berhane N and 7 others. J Pharmacokinet Pharmacodyn, 2013. Cited by 55 papers, by iCite.
Cite this record
ConductScience Library. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. Papers, record 23933716. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23933716
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies | Major topic |
| Antineoplastic Agents | Major topic |
| Immunoconjugates | Major topic |
| Neoplasms, Experimental | Major topic |
| Ado-Trastuzumab Emtansine | |
| Animals | |
| Antibodies, Monoclonal, Humanized | |
| Cell Line, Tumor | |
| Female | |
| Humans | |
| Maytansine | |
| Mice | |
| Mice, Nude | |
| Trastuzumab | |
| Xenograft Model Antitumor Assays |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20424896 | Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. | J Pharmacokinet Pharmacodyn | 2010 | https://conductscience.org/library/papers/20424896 | PubMed |
| 2 | 19769391 | Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. | Bioconjug Chem | 2010 | https://conductscience.org/library/papers/19769391 | PubMed |
| 3 | 14519650 | Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14519650 | PubMed |
| 4 | 17264369 | Investigation of various growth mechanisms of solid tumour growth within the linear-quadratic model for radiotherapy. | Phys Med Biol | 2007 | https://conductscience.org/library/papers/17264369 | PubMed |
| 5 | 10367667 | Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. | Toxicol Pathol | 1999 | https://conductscience.org/library/papers/10367667 | PubMed |
| 6 | 15967831 | Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. | Oncologist | 2005 | https://conductscience.org/library/papers/15967831 | PubMed |
| 7 | 20204473 | Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling. | J Pharmacokinet Pharmacodyn | 2010 | https://conductscience.org/library/papers/20204473 | PubMed |
| 8 | 14871843 | Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. | Cancer Res | 2004 | https://conductscience.org/library/papers/14871843 | PubMed |
| 9 | 16417259 | Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. | Bioconjug Chem | 2006 | https://conductscience.org/library/papers/16417259 | PubMed |
| 10 | 18061880 | The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. | Drug Discov Today | 2007 | https://conductscience.org/library/papers/18061880 | PubMed |
| 11 | 12646013 | Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. | AAPS PharmSci | 2002 | https://conductscience.org/library/papers/12646013 | PubMed |
| 12 | 19837907 | Interspecies scaling of therapeutic monoclonal antibodies: initial look. | J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19837907 | PubMed |
| 13 | 19896825 | The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. | Curr Opin Biotechnol | 2009 | https://conductscience.org/library/papers/19896825 | PubMed |
| 14 | 20421541 | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20421541 | PubMed |
| 15 | 20962582 | Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? | MAbs | 2011 | https://conductscience.org/library/papers/20962582 | PubMed |
| 16 | 15120038 | Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. | Eur J Cancer | 2004 | https://conductscience.org/library/papers/15120038 | PubMed |
| 17 | 19047765 | Mathematical modeling of liver metastases tumour growth and control with radiotherapy. | Phys Med Biol | 2008 | https://conductscience.org/library/papers/19047765 | PubMed |
| 18 | 23151991 | Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. | J Pharmacokinet Pharmacodyn | 2012 | https://conductscience.org/library/papers/23151991 | PubMed |
| 19 | 12271329 | A guide to the new ARENA/OLAW IACUC guidebook. | Lab Anim (NY) | 2002 | https://conductscience.org/library/papers/12271329 | PubMed |
| 20 | 19902363 | Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. | AAPS J | 2010 | https://conductscience.org/library/papers/19902363 | PubMed |
Cited by40
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42978398 | Design to Dose: Integrating Quantitative Insights Across the Antibody Drug Conjugate (ADC) Development Lifecycle. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42978398 | PubMed |
| 42883992 | From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883992 | PubMed |
| 41900840 | Applications of Pharmacometrics in Antibody-Drug Conjugate Development. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41900840 | PubMed |
| 41854808 | Industry Practices in Monoclonal Antibody Tissue Biodistribution Assessment: An IQ Consortium Cross-Industry Survey of Current Approaches and Emerging Trends. | AAPS J | 2026 | https://conductscience.org/library/papers/41854808 | PubMed |
| 41304790 | Practical Pharmacokinetic-Pharmacodynamic Models in Oncology. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41304790 | PubMed |
| 41184856 | Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41184856 | PubMed |
| 41145622 | Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/41145622 | PubMed |
| 38532525 | Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression. | CPT Pharmacometrics Syst Pharmacol | 2024 | https://conductscience.org/library/papers/38532525 | PubMed |
| 37787918 | Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs). | J Pharmacokinet Pharmacodyn | 2024 | https://conductscience.org/library/papers/37787918 | PubMed |
| 37408311 | Therapeutic index improvement of antibody-drug conjugates. | MAbs | 2023 | https://conductscience.org/library/papers/37408311 | PubMed |
| 37380821 | A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models. | AAPS J | 2023 | https://conductscience.org/library/papers/37380821 | PubMed |
| 37259689 | Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88. | Clin Transl Sci | 2023 | https://conductscience.org/library/papers/37259689 | PubMed |
| 37111619 | Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37111619 | PubMed |
| 35806163 | Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35806163 | PubMed |
| 35712824 | Development of and insights from systems pharmacology models of antibody-drug conjugates. | CPT Pharmacometrics Syst Pharmacol | 2022 | https://conductscience.org/library/papers/35712824 | PubMed |
| 35439371 | Quantitative systems pharmacology modeling provides insight into inter-mouse variability of Anti-CTLA4 response. | CPT Pharmacometrics Syst Pharmacol | 2022 | https://conductscience.org/library/papers/35439371 | PubMed |
| 35024323 | Target-responsive subcellular catabolism analysis for early-stage antibody-drug conjugates screening and assessment. | Acta Pharm Sin B | 2021 | https://conductscience.org/library/papers/35024323 | PubMed |
| 34530672 | Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. | MAbs | 2021 | https://conductscience.org/library/papers/34530672 | PubMed |
| 33922017 | The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/33922017 | PubMed |
| 32710210 | Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. | J Pharmacokinet Pharmacodyn | 2020 | https://conductscience.org/library/papers/32710210 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TPBG | 7162 | PubTator's text mining | https://conductscience.org/library/genes/7162 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23933716
GET https://conductscience.org/api/papers/v1/23933716/references?page=2